Doctors probe heart impact of amyloidosis drugs
NCT ID NCT05873868
Summary
This study aims to better understand how two existing drugs, patisiran and vutrisiran, affect the heart in patients with a rare inherited disease called hereditary transthyretin amyloidosis (ATTRv). Researchers will observe 20 patients who have both nerve and heart symptoms and are starting one of these drugs. They will use heart scans and questionnaires over two years to see if and how the treatment changes heart structure and function.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRANSTHYRETIN AMYLOIDOSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
APHP Henri Mondor
Créteil, France
-
CHU Bordeaux Haut-Levêque
Bordeaux, France
-
CHU Grenoble Alpes
Grenoble, France
-
CHU Nancy Institut Louis Mathieu
Nancy, France
-
CHU Rangueil Toulouse
Toulouse, France
Conditions
Explore the condition pages connected to this study.